News

In a study of children with food allergy and atopic dermatitis, longer dupilumab use was associated with significantly lower food-specific IgE levels.

Recent FDA approvals of pegcetacoplan and iptacopan revolutionize C3 glomerulopathy treatment, offering hope and targeted options for patients.

C3G treatment options expand with FDA approvals of pegcetacoplan and iptacopan, offering new hope for patient care.

This segment of Hebert’s DERM 2025 interview highlights additional conclusions from her team’s data on roflumilast in atopic dermatitis among infants and toddlers.

A 4.5 mm cut-off using the Skin Prick Automated Test showed comparable accuracy to the standard skin prick test in detecting birch pollen and house dust mite allergies.

Check out expert perspectives and new research on hepatitis C, cirrhosis, and more in this July 2025 recap.

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

Investigators believe this connection could be used to prognosticate and prevent future cases of diabetic retinopathy.

The combination therapy of aflibercept and micropulsed yellow laser treatment results in good anatomical responses and substantially fewer intravitreal injections.

Interim data from the ongoing TEASE-3 trial have indicated preservation of best-corrected visual acuity.

Compared to sham treatment, the PER-001 implant is safe, efficacious, and effective in reducing macular ischemia, vascular leakage, and microaneurysms.

Based on an open-label extension of the OAKS and DERBY trials, pegcetacoplan has highlighted the superior effectiveness of early versus delayed GA treatment.

Insights from Lungcast Interviews with Experts Leading the Charge in Detection and Therapy

Results from the DAVIO 2 trial have shown the equivalence of a single dose of EYP-1901 to aflibercept Q8W in visual acuity over 6 months.

In a DERM 2025 conference interview, Hebert highlights takeaways from her team’s findings on roflumilast cream in patients aged 3 months to 2 years with atopic dermatitis.

This FDA News Month in Review provides a round-up of regulatory decisions from July 2025.

Post hoc analyses of the TENAYA and LUCERNE phase 3 trials indicated important endpoints that could signal the potential for treatment interval extension.

This month in review spotlights 6 headlines, from the FDA approving sebetralsta for HAE to NICE Recommending Betula Verrucosa for Birch Tree Allergy.

Panelists discuss differentiators between nsMRA and steroidal MRAs in the context of heart failure.

Panelists offer perspective on the role of finerenone in combination therapy approaches in patients with HFmrEF/HFpEF.

Finerenone's FDA approval marks a transformative step in heart failure treatment, offering early benefits and broad applicability.

Finerenone's FDA approval marks a breakthrough in heart failure treatment, significantly reducing cardiovascular events and hospitalizations for patients.

From clinical trial updates in IBD to novel research about IBS and other disorders of gut brain interaction, catch up on the latest headlines in GI.

Three-year PIONEER data show avapritinib provides lasting symptom relief in indolent systemic mastocytosis with good safety.

EYP-1901 successfully achieved an extended time to first supplemental treatment versus aflibercept, indicating a potential for further dose interval extension.

Hahn discusses his recent study evaluating AREDS’s potential for nonsubfoveal GA regression in response to a recent post hoc analysis.

Patient responses indicate that the device is simple and easy to use, and clinical data reflects its effectiveness in recognizing hallmark signals of AMD.

The therapy was originally approved under the name Alhemo for people with hemophilia ages 12 and up without inhibitors.